Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies plans to extend the expiry date of 1,000,000 share purchase warrants by three years, highlighting their ongoing commitment to advancing cancer treatment technologies. The warrants, which were initially issued in November 2022, remain exercisable at $0.35 per share, pending approval from the TSX Venture Exchange.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Get Ready for the Next Leg Up,’ Says Piper Sandler About Nvidia Stock
- M&A News: Paramount’s (NASDAQ:PARA) Merger with Skydance May Get Delayed
- Ford (NYSE:F) Cuts Hours At German EV Plant
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
